ArticleFrontiers in pharmacology2026
An integrated network toxicology and multi-omics framework prioritizes BRCA1 as a testable candidate in benzo[a]pyrene-associated oral cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Environmental exposure to benzo[a]pyrene (BaP) is a recognized risk factor for oral cancer, but systematic strategies for prioritizing candidate molecular nodes and generating experimentally testable hypotheses remain limited. Here, we conducted a hypothesis-generating, methodologically oriented exploratory study using an integrated three-tier framework comprising computational target prioritization, multi-omics contextualization, and preliminary phenotypic assessment. Network toxicology identified four genes shared between the predefined BaP-associated and oral cancer-related gene sets: EGFR, HRAS, TP53, and BRCA1. These genes constituted the complete intersection and were not ordered by a composite score. BRCA1 was selected as a study-specific, testable candidate for focused follow-up based on convergent expression, protein-context, and DNA-damage-response evidence. Exploratory docking and molecular dynamics analyses characterized a predicted BaP-BRCA1 structural model but did not establish direct biochemical binding. Single-cell and spatial transcriptomic analyses described the baseline distribution of BRCA1 across tumor, immune, and stromal compartments but lacked BaP exposure annotations. Separately, BaP treatment was accompanied by increased proliferation and BRCA1 mRNA expression in CAL27 and SCC9 cells, whereas BRCA1 knockdown attenuated BaP-associated proliferation and was accompanied by changes in p53-axis transcript and protein readouts. This exploratory study prioritizes BRCA1 as a testable candidate and illustrates the utility of integrating network toxicology with multi-omics contextualization. The current findings do not establish direct BaP-BRCA1 binding, direct regulation of BRCA1 by BaP, a definitive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.